13F Insight
DOSSIER · 13F-HR · Q4 2025

Scientech Research LLC

$159M in tracked AUM across 479 positions as of Q4 2025.

SR
CIK 0002011556 · last filed Dec 31, 2025
Total AUM
$159M
as of Q4 2025
Holdings
479
—
positions
Whale Score
33
33
tracked
Activity
—
no data
changes this Q
AI Analysis · Q4 2025

Assets under management fell from $287M to $159M and the holdings were virtually entirely replaced. 44 positions exited and 44 new ones initiated — a structural reset that fundamentally changes what this manager owns. Here is what the new book looks like, and why it matters.

What Was Sold

The prior quarter's holdings were recognizable as a concentrated, thematic set: Eli Lilly and Regeneron (large-cap biotech), Alnylam (RNA therapeutics), Insulet (diabetes tech), UniQure (gene therapy), Tilray (cannabis), Zebra Technologies (enterprise IoT), MongoDB (cloud database), and a Nvidia position that at 0.7% already signaled some of the broad-cap tech exposure Main Street Research and similar managers were trimming. Together these names represented the core thesis of the prior book. Every one of them is gone in Q4, along with Robinhood, CoreWeave, Terawulf, and Transocean. The exits are not selective profit-taking — they are comprehensive.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q4 2025. Methodology

Quarter at a glance — Q4 2025

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q4 2025.

#HoldingValueSharesWeight
01
ONDS
ONDAS HLDGS INC
$2M197K1.2%02
DPZ
DOMINOS PIZZA INC
$1M3K0.9%03
AMD
ADVANCED MICRO DEVICES INC
$1M6K0.9%04
MDLN
MEDLINE INC
$1M30K0.8%05
APP
APPLOVIN CORP
$1M2K0.8%06
CCL
CARNIVAL CORP
$1M40K0.8%07
NOC
NORTHROP GRUMMAN CORP
$1M2K0.7%08
GEV
GE VERNOVA INC
$1M2K0.7%09
RARE
ULTRAGENYX PHARMACEUTICAL IN
$1M48K0.7%10
DY
DYCOM INDS INC
$1M3K0.7%

Filing history

2025Q4Dec 31
$159M▼ 44.6%
479 positionsView →2025Q3Sep 30
$287M▼ 29.9%
550 positionsView →2025Q2Jun 30
$409M▲ 8.3%
572 positionsLocked2025Q1Mar 31
$378M▲ 6.9%
541 positionsLocked2024Q4Dec 31
$353M▼ 29.7%
550 positionsLocked2024Q3Sep 30
$502M▲ 3.4%
590 positionsLocked2024Q2Jun 30
$485M▲ 157.3%
563 positionsLocked2024Q1Mar 31
$189M▲ 87.8%
394 positionsLocked2023Q4Dec 31
$100M—
310 positionsLocked